Owner Scorecard


← All companies ← FELE Manual FERG → ← FDMT Biotechnology GILD →

FENC, Fennec Pharmaceuticals Inc.

Biotechnology consumer brand UnprofitableDistress / turnaround

A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.

Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.

In the United States, we sell our product through an experienced field force including Regional Pediatric Oncology Specialists and we utilize medical science liaisons within our medical team who help educate the medical communities and patients about CIO and our programs supporting patient access to PEDMARK .

Latest annual: FY2025 10-K
FENC · Fennec Pharmaceuticals Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$45M
−6.1% YoY
Vital signs · TTM, with 5-yr average
Revenue $59M 5-yr avg $23M
Operating margin −1.9% 5-yr avg −22.9%
ROIC −74% 5-yr avg −167%

Next report By 11/13 · the 10-Q for the quarter ended late September · due within 45 days of period end · has filed ~44 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has run around −14% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 25% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

Most recent quarterly filing 10-Q filed Aug 13, 2026 Source at SEC EDGAR →

Revenue up 85.2% year over year

figures computed from the filing's XBRL

The record, 2015–2025

realized figures from each filing · older years to the left
2015’152016’162017’172018’182019’192020’202022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$0$0$0$0$0$170K$2M$21M$48M$45M$59MRevenueRevenue
$1M$20M$58MGross profitGross prof.
94%94%98%Gross marginGross mgn
n/mn/m154%87%105%95%SG&A / revenueSG&A/rev
n/m230%0%1%1%0%R&D / revenueR&D/rev
($2M)($3M)($7M)($10M)($13M)($18M)($23M)($13M)$3M($6M)($1M)Operating incomeOp. inc.
n/mn/m−60.1%5.4%−14.1%−1.9%Operating marginOp. mgn
($658K)($3M)($7M)($16M)($71K)($10M)Pretax incomePretax
($659K)($3M)($7M)($10M)($13M)($18M)($24M)($16M)($436K)($10M)($3M)Net incomeNet inc.
Cash flow & returns
($2M)($2M)($4M)($8M)($9M)($16M)($18M)($17M)$27M($12M)($2M)Operating cash flowOp. cash
($1M)$50K$2M$237K$1M($277K)$2M($6M)$22M($10M)($6M)Working capital & otherWC & other
$0$0$0$0Investing cash flowInv. cash
$497K$5M$28M$2M($71K)$32M$21M$7M($14M)$23MFinancing cash flowFin. cash
($1M)$3M$24M($5M)Change in cashΔ cash
-120%-78%-26%-46%-108%-62%-27%-8%Return on equityROE
−120%−78%−26%−46%−108%−62%−27%−8%Retained to equityRetained/eq
Balance sheet
$942K$4M$28M$23M$14M$30M$24M$13M$27M$37M$41MCash & investmentsCash+inv
$297K$244K$855K$1M$2M$2M$2M$4M$3M$5M$6MAccounts payablePayables
$23M$14M$31M$27M$27M$44M$67M$73MCurrent assetsCur. assets
$471K$402K$2M$2M$2M$2M$5M$8M$7M$11M$12MCurrent liabilitiesCur. liab.
14.0×6.1×13.4×5.8×3.6×6.4×6.4×5.8×Current ratioCurr. ratio
$1M$4M$28M$23M$14M$31M$27M$27M$45M$71M$76MTotal assetsAssets
$25M$31M$19MTotal debtDebt
$1M$18M($7M)Net debt / (cash)Net debt
$471K$402K$2M$2M$2M$2M$30M$38M$51M$35MTotal liabilitiesTotal liab.
$548K$4M$27M$21M$12M$29M($3M)($12M)($6M)$35M$42MShareholders’ equityEquity
n/m266.3%25.2%10.6%15.8%12.7%Stock comp / revenueSBC/rev
Per share
10.8M12.8M15.0M18.9M19.9M23.7M26.3M26.6M27.3M28.6M37.4MShares out (diluted)Shares
$0.00$0.00$0.00$0.00$0.00$0.01$0.06$0.80$1.74$1.56$1.58Revenue / shareRev/sh
$-0.06$-0.22$-0.47$-0.52$-0.64$-0.76$-0.90$-0.60$-0.02$-0.34$-0.09EPS (diluted)EPS
$0.05$0.28$1.78$1.13$0.60$1.23$-0.10$-0.44$-0.22$1.24$1.13Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
10-yr5-yr
Revenue / share+193.5%/yr
Book value / share+37.7%/yr+0.2%/yr
III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash
    Cash $37M − debt $19M
    What this means

    Cash and short-term investments exceed every dollar of debt by $17M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average
    NOPAT ($5M) ÷ invested capital $18M (debt + equity − cash)
    Industry peers: median -37%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Not enough data
    Industry peers: median -244%
    What this means

    The filing data didn't include the inputs for this check.

  • Loss, and burning cash
    Net income ($10M) · cash from operations ($12M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting?
    Not enough data
    What this means

    The filing data didn't include the inputs for this check.

The promise and the pay packet

  • Heavy selling cost
    Selling and marketing $19M ÷ revenue $45M
    What this means

    Sales and marketing as a share of revenue, kept apart from administrative overhead because it answers a different question: how much a business must spend to win the next customer. A company whose product pulls customers in spends little here and keeps the difference; one that must buy its growth is running to stand still, and the spending has to keep rising for revenue to keep rising. Read it beside the growth rate, not alone.

  • Is the buyback buying ownership, or mopping up? 15.8%
    The count is rising
    Stock compensation $7M (fiscal 2025), 15.8% of revenue · no repurchases · diluted shares +8.8% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $45M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 6.37×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $19M vs $57M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 10 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.25/share (latest year $-0.28), the averaged base the calculator's gate runs on, and book value is $1.01/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2015–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 10
    What this means

    Lost money in 10 year(s), look at what happened there before trusting the average.

  • Operating margin −5996% → −4% (2-yr avg ends)
    What this means

    Through the cycle the operating margin widened — about −5996% early to −4% lately, median −60% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2020 · −10520.6% op. margin
    What this means

    Operations went underwater in 2020, understand why before trusting the good years.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$73M
  • Cash & short-term investments$41M
  • Other current assets$31M
Current liabilities$12M
  • Accounts payable$6M
  • Other current liabilities$7M
Current ratio5.85×all current assets ÷ what's due · Graham looked for 2×
Quick ratioinventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio3.33×strictest: cash alone against what's due
Working capital$60Mthe cushion left after near-term bills
Cash runway20.2 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+85.2%the freshest read on whether the business is still growing
Current ratio, recent quarters7.8× → 5.8×
Deeper floors
Tangible book value$42Mequity stripped of goodwill & intangibles
Net current asset value$39MGraham's net-net: current assets less all liabilities
Deferred revenue$24Mcustomer cash collected before delivery; operating float

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearPay, as filed“Actually paid”Net income
2023$2.5M$4.5M($16M)
2024$1.6M$1.9M($436K)
2024$3.2M$2.0M($436K)
2025$1.7M$815k($10M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Net income is the whole business's, as filed, for the same fiscal years.

  • Insider ownership10.7%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$7M

    The slice of the business handed to employees in shares in fiscal 2025, 15.8% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Revenue recognition, Credit & receivables, Stock compensation as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Biotechnology

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
CGENCompugen Ltd.$73M88%-92.0%-37%-92%
VIRVir Biotechnology Inc.$69M95%4y-544.0%-45%-417%
MESOMesoblast Limited$65M70%1y-488.4%-11%-571%2y
PLXProtalix BioTherapeutics Inc. (DE)$53M59%-23.5%-1%4y-33%
FENCFennec Pharmaceuticals Inc.$45M94%2y-14.1%3y-167%1y
KYMRKymera Therapeutics Inc.$39M0%-277.5%-26%-256%
CCCCC4 Therapeutics Inc.$36M-336.1%-50%-276%
XFORX4 Pharmaceuticals Inc.$35M76%2y-247.4%1y-175%-244%1y
Group median76%-262.5%-41%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

The owner-earnings base could not be formed from this filing’s tagged data (operating cash flow or capital spending is missing), so the owner-earnings reverse-DCF has no base to grow. We read the price from both ends instead: type a price to see the profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Fennec Pharmaceuticals Inc. (FENC), the owner's record," https://ownerscorecard.com/c/FENC, data as of 2026-08-17.

Manual order: ← FELE its page in the Manual FERG →

Industry order: ← FDMT the Biotechnology chapter GILD →